Your browser is no longer supported. Please, upgrade your browser.
Settings
CLDX Celldex Therapeutics, Inc. daily Stock Chart
CLDX [NASD]
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.10 Insider Own0.40% Shs Outstand127.86M Perf Week-5.95%
Market Cap323.49M Forward P/E- EPS next Y-0.96 Insider Trans0.00% Shs Float127.48M Perf Month7.20%
Income-124.70M PEG- EPS next Q-0.27 Inst Own59.70% Short Float10.34% Perf Quarter7.20%
Sales9.50M P/S34.05 EPS this Y3.40% Inst Trans-8.92% Short Ratio10.21 Perf Half Y-24.93%
Book/sh1.85 P/B1.37 EPS next Y7.70% ROA-37.20% Target Price7.30 Perf Year-30.68%
Cash/sh1.20 P/C2.10 EPS next 5Y- ROE-51.90% 52W Range2.20 - 5.02 Perf YTD-28.53%
Dividend- P/FCF- EPS past 5Y-2.20% ROI-50.10% 52W High-49.60% Beta2.68
Dividend %- Quick Ratio5.60 Sales past 5Y-6.00% Gross Margin- 52W Low15.00% ATR0.11
Employees205 Current Ratio5.60 Sales Q/Q171.40% Oper. Margin- RSI (14)51.94 Volatility3.74% 3.59%
OptionableYes Debt/Eq0.00 EPS Q/Q29.40% Profit Margin- Rel Volume0.51 Prev Close2.53
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume1.29M Price2.53
Recom2.40 SMA201.16% SMA502.90% SMA200-17.35% Volume521,722 Change0.00%
Aug-01-17Resumed H.C. Wainwright Buy $10
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-04-12Initiated Cantor Fitzgerald Buy $7
Sep-12-17 04:01PM  Celldex Announces Departure of Chief Medical Officer GlobeNewswire
Sep-11-17 10:18PM  ETFs with exposure to Celldex Therapeutics, Inc. : September 12, 2017 Capital Cube
Sep-08-17 08:00AM  Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. ACCESSWIRE -5.80%
Aug-31-17 05:44PM  ETFs with exposure to Celldex Therapeutics, Inc. : August 31, 2017 Capital Cube
Aug-29-17 08:35AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 29, 2017 Capital Cube
Aug-24-17 10:03PM  3 Top Healthcare Stocks to Buy Now Motley Fool
05:42PM  Celldex Ends Phase II Enrollment for Breast Cancer Candidate Zacks
11:33AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-23-17 09:15AM  Celldex Announces Completion of Enrollment in Phase 2b Study of Glembatumumab Vedotin in Triple Negative Breast Cancer GlobeNewswire
Aug-19-17 12:03PM  3 Top Biotech Stocks Under $10 Motley Fool
Aug-16-17 08:15PM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : August 17, 2017 Capital Cube
Aug-14-17 09:37AM  3 Beaten-Up Biotech Stocks: Are They Bargains? Motley Fool
08:26AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 14, 2017 Capital Cube
02:11AM  Edited Transcript of CLDX earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 10:48AM  Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up Zacks
08:02AM  Celldex Therapeutics, Inc. Finishes Second Quarter With Plenty of Cash and Clinical Momentum Motley Fool
Aug-08-17 11:55PM  Celldex reports 2Q loss Associated Press
04:01PM  Celldex Reports Second Quarter 2017 Results GlobeNewswire
Aug-04-17 08:22AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : August 4, 2017 Capital Cube
Aug-02-17 11:30AM  Celldex to Report Second Quarter 2017 Financial Results and Host Corporate Update Call GlobeNewswire
09:20AM  What's in the Cards for Celldex (CLDX) this Earnings Season? Zacks
Jul-19-17 06:30AM  Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics Motley Fool
Jul-14-17 07:01PM  Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain? Motley Fool
Jun-24-17 11:42AM  3 Stocks That Could Double Your Money Motley Fool
Jun-18-17 02:32PM  3 Stocks with Universal Display-like Return Potential Motley Fool
Jun-16-17 08:01AM  Celldex Therapeutics Announces Additions to the Board of Directors and Senior Management Team GlobeNewswire
Jun-13-17 07:17AM  Why Is Celldex (CLDX) Down 27% Since the Last Earnings Report? Zacks
Jun-12-17 08:42AM  3 Beaten-Up Biotech Stocks: Are They Bargains? Motley Fool
Jun-11-17 09:47AM  3 Stocks That Look Just Like Oracle in 1986 Motley Fool
Jun-07-17 08:00AM  Today's Research Reports on Stocks to Watch: Celldex Therapeutics and Pandora Media Accesswire -5.86%
Jun-06-17 04:53PM  Here's Why Celldex Therapeutics, Inc. Fell Today Motley Fool -12.45%
04:01PM  Celldex Therapeutics to Participate in the Jefferies 2017 Global Healthcare Conference GlobeNewswire
Jun-05-17 04:27PM  Celldex Therapeutics Presents Phase 1 Study of Varlilumab and Opdivo® at 2017 ASCO Annual Meeting GlobeNewswire -5.54%
04:17PM  Here's What Shaved 14% Off Celldex Therapeutics, Inc.'s Stock Price in May Motley Fool
02:08PM  ETFs with exposure to Celldex Therapeutics, Inc. : June 5, 2017 Capital Cube
11:24AM  Celldex Presents Promising Overall Survival Data from Phase 2 Study of Single-agent Glembatumumab Vedotin in Patients with Checkpoint-Refractory Metastatic Melanoma GlobeNewswire
Jun-02-17 09:49AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
Jun-01-17 09:39AM  Celldex Therapeutics, Inc.: The Bear Case from a Bull Motley Fool
May-30-17 12:26PM  George O. Elston Named Chief Executive Officer of 2X Oncology GlobeNewswire
May-26-17 09:31AM  Celldex's Immuno-Oncology Pipeline Continues to Impress Zacks
May-21-17 06:41AM  Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc. Motley Fool
May-18-17 07:44AM  3 Value Stocks for Bold Investors Motley Fool
May-17-17 05:01PM  Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting GlobeNewswire
May-10-17 10:30AM  Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up Zacks
08:50AM  3 Stocks That Could Double Your Investment Motley Fool
May-09-17 05:41PM  Celldex Therapeutics, Inc.'s Collaboration with Bristol-Myers Squibb Key in First-Quarter Update Motley Fool
05:34PM  Celldex reports 1Q loss Associated Press
04:01PM  Celldex Reports First Quarter 2017 Results GlobeNewswire
May-02-17 11:33AM  Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store? Zacks
Apr-23-17 02:03PM  Read This Before You Buy Biotech Stocks Motley Fool
Apr-21-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Celldex Therapeutics and Spectrum Pharmaceuticals Accesswire
Apr-20-17 10:21AM  Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards? Zacks
10:16AM  What's in Store for Biogen (BIIB) this Earnings Season? Zacks
Apr-19-17 02:16PM  ETFs with exposure to Celldex Therapeutics, Inc. : April 19, 2017 Capital Cube
03:26AM  Why Is Celldex (CLDX) Down 4.4% Since the Last Earnings Report? Zacks
Apr-17-17 08:42AM  3 Cancer Drug Stocks That Could Make You Rich Motley Fool
Apr-15-17 12:02PM  3 Biotech Stocks to Buy on Sale Motley Fool
Apr-07-17 04:11PM  ETFs with exposure to Celldex Therapeutics, Inc. : April 7, 2017 Capital Cube
11:09AM  3 Stocks That Could Double Your Money Motley Fool
Apr-01-17 12:02PM  3 Top Stocks You've Been Overlooking Motley Fool
12:02PM  3 Top Stocks You've Been Overlooking at Motley Fool
Mar-31-17 09:30AM  Today's Research Reports on Stocks to Watch: Celldex Therapeutics and PDL BioPharma Accesswire
Mar-30-17 08:12AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March 30, 2017 Capital Cube
08:12AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March 30, 2017
Mar-27-17 03:52PM  ETFs with exposure to Celldex Therapeutics, Inc. : March 27, 2017 Capital Cube
03:52PM  ETFs with exposure to Celldex Therapeutics, Inc. : March 27, 2017
Mar-25-17 12:03PM  3 Stocks That Could Double Your Money at Motley Fool
Mar-21-17 09:25AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube -5.93%
09:25AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-20-17 10:01AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017
Mar-18-17 01:04PM  CELLDEX THERAPEUTICS, INC. Financials
Mar-17-17 08:10AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March 17, 2017
Mar-15-17 10:55AM  Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat Zacks
12:58AM  Edited Transcript of CLDX earnings conference call or presentation 14-Mar-17 8:30pm GMT Thomson Reuters StreetEvents
Mar-14-17 06:23PM  Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing Motley Fool
06:23PM  Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing at Motley Fool
04:30PM  Celldex Therapeutics Inc Earnings and Corporate Strategy Call scheduled for 4:30 pm ET today
04:26PM  CELLDEX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:14PM  Celldex reports 4Q loss Associated Press
04:01PM  Celldex Provides Corporate Update and Reports Full Year 2016 Results GlobeNewswire
07:07AM  Q4 2016 Celldex Therapeutics Inc Earnings Release - After Market Close
Mar-12-17 07:21AM  3 Horrible Stocks for Retirees at Motley Fool
Mar-10-17 02:42PM  Better Buy: Agenus Inc. vs. Celldex Therapeutics at Motley Fool
Mar-09-17 09:15AM  Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat
Mar-08-17 09:30AM  Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Celldex Therapeutics and Mast Therapeutics Accesswire
Mar-07-17 04:43PM  Celldex Therapeutics, Inc. Is Feeling Some Pressure Today -- Here's Why at Motley Fool -9.19%
Mar-06-17 11:03AM  Why Celldex Therapeutics Stock Gained 10% in February at Motley Fool
08:46AM  Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
Mar-03-17 08:03AM  3 Stocks That Could Double Your Money at Motley Fool
Mar-01-17 04:05PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F
04:01PM  Celldex Therapeutics Announces Appointment to Board of Directors GlobeNewswire
Feb-24-17 05:42PM  3 Biotech Long Shots: Boom Or Bust? at Motley Fool
Feb-23-17 07:44PM  Looking Back at David Gardner's Worst Stock Picks of the Past 3 Years at Motley Fool
Feb-13-17 02:45PM  Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call GlobeNewswire
Feb-09-17 09:48AM  Why Celldex Therapeutics Stock Fell by Almost 10% in January at Motley Fool
Feb-07-17 04:04PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statem
Feb-06-17 07:45AM  3 Stocks That Could Make You Rich at Motley Fool
Feb-03-17 09:30AM  Mergers & Acquisitions Could be a Key Catalyst for Biotech Stocks in 2017: Today's Reports on Cellect Biotechnology and Celldex Therapeutics Accesswire
Feb-01-17 08:14AM  Forget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys at Motley Fool
Jan-30-17 03:12PM  3 Biotech Stocks I'd Buy Right Now at Motley Fool
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.